CLINICAL TRIALS PROFILE FOR MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for Magnesium Sulfate In Dextrose 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002146 ↗	Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study	Completed	Astra USA	Phase 4	1969-12-31	To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate. To determine whether reductions in ionized magnesium, ionized calcium, and parathyroid hormone levels following foscarnet infusions are lessened by preinfusion of magnesium sulfate. To evaluate the safety of intravenous magnesium sulfate prior to foscarnet infusion by monitoring blood pressure, heart rate, and heart rhythm. To characterize the effect of magnesium sulfate on foscarnet blood levels and urinary excretion of calcium, magnesium, phosphate, and foscarnet.
NCT00004399 ↗	Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	Completed	University of Utah	N/A	1995-09-01	OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
NCT00004399 ↗	Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia	Completed	FDA Office of Orphan Products Development	N/A	1995-09-01	OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
NCT00004730 ↗	Magnesium Sulfate For Brain Injury	Completed	University of Washington	Phase 3	1998-08-01	The purpose of the study is to determine whether magnesium sulfate, given within 8 hours of a moderate or severe traumatic brain injury improves survival, decreases the number of people developing seizures, improves the survivors' mental and psychological functioning, including the ability to return to daily life, live independently, and return to work or school.

Clinical Trial Conditions for Magnesium Sulfate In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Magnesium Sulfate In Dextrose 5% In Plastic Container
Intervention	Trials
Postoperative Pain	21
Preeclampsia	11
Magnesium Sulfate	11
Asthma	10

Condition MeSH

Condition MeSH for Magnesium Sulfate In Dextrose 5% In Plastic Container
Intervention	Trials
Pain, Postoperative	37
Pre-Eclampsia	26
Obstetric Labor, Premature	17
Asthma	16

Clinical Trial Locations for Magnesium Sulfate In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Magnesium Sulfate In Dextrose 5% In Plastic Container
Location	Trials
United States	130
Egypt	84
Korea, Republic of	18
Brazil	17
Canada	12

Trials by US State

Trials by US State for Magnesium Sulfate In Dextrose 5% In Plastic Container
Location	Trials
California	13
New York	9
Ohio	9
Pennsylvania	8
Illinois	7

Clinical Trial Progress for Magnesium Sulfate In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Magnesium Sulfate In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Phase 4	82
Phase 3	43
Phase 2/Phase 3	23

Clinical Trial Status

Clinical Trial Status for Magnesium Sulfate In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	148
Recruiting	58
Not yet recruiting	48

Clinical Trial Sponsors for Magnesium Sulfate In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Magnesium Sulfate In Dextrose 5% In Plastic Container
Sponsor	Trials
Assiut University	33
Cairo University	17
Seoul National University Bundang Hospital	13

Sponsor Type

Sponsor Type for Magnesium Sulfate In Dextrose 5% In Plastic Container
Sponsor	Trials
Other	394
NIH	13
Industry	12